Nightstar
AcquiredOxford, United Kingdom · Founded 2014 · $99.1M raised
- Headquarters
- Oxford
- Employees
- 51–200
- Founded
- 2014
- Business Model
- B2B
- Website
- nightstartx.com
- Total Funding
- $99.1M
- Last Round
- $45.0M Series CJun 2017
- Rounds
- 4
About
Nightstar Therapeutics was an Oxford University spinout developing adeno-associated virus (AAV) gene therapies for inherited retinal diseases including choroideremia and retinitis pigmentosa. Founded in 2014, it completed a NASDAQ IPO in 2017 and was acquired by Biogen for approximately $800 million in June 2019.
Summary
Nightstar is a Biotech company based in Oxford, United Kingdom, founded in 2014. It has raised $99.1M in total across 4 rounds, most recently a $45.0M Series C round in Jun 2017.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2019
Sign up to see all 6 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Global contract research organization providing comprehensive drug development and laboratory ser...